Adverse events of cetuximab sarotalocan in photoimmunotherapy: insights from the Japanese adverse drug event report database
Cancer Chemotherapy and Pharmacology · 12.08.2026 · 96 (1)
DOI: 10.1007/s00280-026-04929-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Chemotherapy and Pharmacology, online erschienen am 12.08.2026. Verfasst von Shiho Ueta und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology and Therapeutics, Tokushima University Graduate School of Biomedical Sciences, 3-18-15 Kuramoto, Tokushima, 770-8…. Hauptthemen laut MEDLINE: Cetuximab, Head and Neck Neoplasms, Immunotherapy, Antineoplastic Agents, Immunological. Die Arbeit nennt 12 Literaturangaben. Gefördert von: Japan Science and Technology Agency.
Themen: Patientensicherheit
Abstract (Originalsprache)
PURPOSE: Cetuximab sarotalocan is an innovative photoimmunotherapy agent for cancer treatment, with an unclear safety profile. We analysed the clinical adverse event profile of cetuximab sarotalocan in photoimmunotherapy. METHODS: In this retrospective study, we analysed real-world clinical data of patients with head and neck cancer from the Japanese Adverse Drug Event Report database. Patient demographics, as well as the nature of adverse events and their outcomes and co-occurrences, were analysed. RESULTS: Cetuximab sarotalocan adverse event reports (n = 227) predominantly included older male patients. The most frequent adverse event was laryngeal oedema, followed by upper respiratory and oral complications. Recovery rates were high for laryngeal oedema and tongue-related adverse events but poor for fistula-related complications. Co-occurrence was found between different adverse events, particularly laryngeal oedema and dysphagia. CONCLUSION: The described safety profile of cetuximab sarotalocan in photoimmunotherapy offers insights for its proper use as well as baseline data for the development and improvement of cancer photoimmunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacology and Therapeutics, Tokushima University Graduate School of Biomedical Sciences, 3-18-15 Kuramoto, Tokushima, 770-8503, Japan.
- Department of Clinical Pharmacology and Therapeutics, Tokushima University Graduate School of Biomedical Sciences, 3-18-15 Kuramoto, Tokushima, 770-8503, Japan. niimura@tokushima-u.ac.jp.
- Department of Clinical and Translational Science, Tokushima University Hospital, Tokushima, Japan. niimura@tokushima-u.ac.jp.
- Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
- Department of Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Japan.
- Department of Pharmacy, Faculty of Pharmaceutical Sciences, Tokushima Bunri University, Tokushima, Japan.
Förderung
- Japan Science and Technology Agency
Zitieren
APA
Ueta, S., Niimura, T., Fujino, S., Goda, M., Ishida, T., Nawa, H., Kawata, E., Tsujinaka, K., Kawada, K., Miyata, K., Horikawa, I., Aizawa, F., Yagi, K., Chuma, M., Izawa-Ishizawa, Y., & Ishizawa, K. (2026). Adverse events of cetuximab sarotalocan in photoimmunotherapy: insights from the Japanese adverse drug event report database. Cancer Chemotherapy and Pharmacology, 96(1). https://doi.org/10.1007/s00280-026-04929-2
Vancouver
Ueta S, Niimura T, Fujino S, Goda M, Ishida T, Nawa H, et al. Adverse events of cetuximab sarotalocan in photoimmunotherapy: insights from the Japanese adverse drug event report database. Cancer Chemotherapy and Pharmacology. 2026;96(1). doi:10.1007/s00280-026-04929-2
BibTeX
@article{Ueta2026,
author = {Ueta, Shiho and Niimura, Takahiro and Fujino, Sakura and Goda, Mitsuhiro and Ishida, Tomoaki and Nawa, Hideki and Kawata, Emika and Tsujinaka, Kaito and Kawada, Kei and Miyata, Koji and Horikawa, Io and Aizawa, Fuka and Yagi, Kenta and Chuma, Masayuki and Izawa-Ishizawa, Yuki and Ishizawa, Keisuke},
title = {Adverse events of cetuximab sarotalocan in photoimmunotherapy: insights from the Japanese adverse drug event report database},
journal = {Cancer Chemotherapy and Pharmacology},
year = {2026},
volume = {96},
number = {1},
doi = {10.1007/s00280-026-04929-2}
}
EUVIMED